312 related articles for article (PubMed ID: 17490732)
1. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
[TBL] [Abstract][Full Text] [Related]
2. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N
J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715
[TBL] [Abstract][Full Text] [Related]
3. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW
Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214
[TBL] [Abstract][Full Text] [Related]
4. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
[TBL] [Abstract][Full Text] [Related]
5. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
[TBL] [Abstract][Full Text] [Related]
6. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
7. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis value of serum soluble B7-H4 expression in non-small cell lung cancer.
Xu CH; Wang W; Wang YC; Lin Y; Zhang XW
Clin Respir J; 2018 Jan; 12(1):134-139. PubMed ID: 27216449
[TBL] [Abstract][Full Text] [Related]
9. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
10. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.
Leung F; Dimitromanolakis A; Kobayashi H; Diamandis EP; Kulasingam V
Clin Biochem; 2013 Oct; 46(15):1462-8. PubMed ID: 23528302
[TBL] [Abstract][Full Text] [Related]
11. Clinical Value of Combined Determination of Serum B7-H4 with Carcinoembryonic Antigen, Osteopontin, or Tissue Polypeptide-Specific Antigen for the Diagnosis of Colorectal Cancer.
Wang P; Li C; Zhang F; Ma X; Gai X
Dis Markers; 2018; 2018():4310790. PubMed ID: 30363700
[TBL] [Abstract][Full Text] [Related]
12. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
13. Serum B7 homologous body 4 for the diagnosis of ovarian cancer in Chinese Han women: A meta-analysis.
Lan Z; Fu D; Xi M
J Cancer Res Ther; 2018 Jun; 14(Supplement):S433-S436. PubMed ID: 29970702
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
[TBL] [Abstract][Full Text] [Related]
15. RCD24, B7-H4 and PCNA expression and clinical significance in ovarian cancer.
Zheng C; Yang R
J BUON; 2019; 24(2):715-719. PubMed ID: 31128028
[TBL] [Abstract][Full Text] [Related]
16. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ
Br J Cancer; 2017 Aug; 117(5):666-674. PubMed ID: 28664912
[TBL] [Abstract][Full Text] [Related]
17. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
18. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
[TBL] [Abstract][Full Text] [Related]
19. Glycomics analysis of serum: a potential new biomarker for ovarian cancer?
Leiserowitz GS; Lebrilla C; Miyamoto S; An HJ; Duong H; Kirmiz C; Li B; Liu H; Lam KS
Int J Gynecol Cancer; 2008; 18(3):470-5. PubMed ID: 17655680
[TBL] [Abstract][Full Text] [Related]
20. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
